Provider: View Press Release
Type: Link
Title: Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review
Description: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review If approved, Dupixent...
Provider: View Press Release
Type: Link
Title: Media Update: Sanofi completes acquisition of Qunol®
Description: Sanofi completes acquisition of Qunol® Paris, September 29, 2023. Sanofi announced today the completion of its acquisition of Qunol, a...
Provider: View Press Release
Type: Link
Title: Media Update: Sanofi presents new data from robust MS clinical pipeline exploring multiple approaches to address important unmet patient needs
Description: Sanofi presents new data from robust MS clinical pipeline exploring multiple approaches to address important unmet patient needs Paris, October 2,...
Provider: View Press Release
Type: Link
Title: Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
Description: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli Extraintestinal pathogenic E. coli (ExPEC)...
Provider: View Press Release
Type: Link
Title: Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment
Description: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment TEV’574, a novel anti-TL1A therapy, is being...
Provider: View Press Release
Type: Link
Title: Media Update: New data at WMS 2023 reaffirm long-term efficacy of Nexviazyme® (avalglucosidase alfa) for the treatment of Pompe disease
Description: New data at WMS 2023 reaffirm long-term efficacy of Nexviazyme® (avalglucosidase alfa) for the treatment of Pompe disease Findings include long-term...